A Survey on Cannabinoid Treatment of Pediatric Epilepsy Among Neuropediatricians in Scandinavia and Germany

Objectives: There is an increasing interest in cannabinoid-based products for the treatment of refractory pediatric epilepsy. However, a licensed cannabidiol (CBD) product was first approved for use by the European regulatory authorities in 2019. We aimed to obtain knowledge about clinical experienc...

Descripción completa

Detalles Bibliográficos
Autores principales: Klingenberg, Claus, Mouslet, George, Hjalgrim, Helle, Gerstner, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396558/
https://www.ncbi.nlm.nih.gov/pubmed/32850532
http://dx.doi.org/10.3389/fped.2020.00416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396558/
https://www.ncbi.nlm.nih.gov/pubmed/32850532
http://dx.doi.org/10.3389/fped.2020.00416

Ejemplares similares